No benefit associated with moxifloxacin use for the treatment of recurrent drug-sensitive tuberculosis.

Although moxifloxacin is one of the most in vitro and in vivo active anti-tuberculosis (TB) drug, large randomized trials showed that it does not allow to reduce treatment duration for drug-sensitive TB. Methods Investigators from the Kwazulu Natal (South Africa) evaluated in an open-label, randomized trial, whether the replacement of ethambutol with moxifloxacin in standar...